Boston Scientific Corp. (BSX)

37.30
0.85 2.23
NYSE : Health Technology
Prev Close 38.15
Open 38.10
Day Low/High 37.28 / 38.13
52 Wk Low/High 26.27 / 40.81
Volume 6.68M
Avg Volume 7.26M
Exchange NYSE
Shares Outstanding 1.39B
Market Cap 52.87B
EPS 1.20
P/E Ratio 32.06
Div & Yield N.A. (N.A)

Latest News

Boston Scientific Announces Scheduled Data At EHRA 2019 Congress

Boston Scientific Announces Scheduled Data At EHRA 2019 Congress

MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March...

Boston Scientific Prices $4.3 Billion Of Senior Notes

Boston Scientific Prices $4.3 Billion Of Senior Notes

MARLBOROUGH, Mass., Feb.

Boston Scientific Announces Results For Fourth Quarter And Full Year 2018

Boston Scientific Announces Results For Fourth Quarter And Full Year 2018

MARLBOROUGH, Mass., Feb.

Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads

Boston Scientific Launches Vercise™ Primary Cell And Vercise Gevia™ Deep Brain Stimulation Systems With Directional Leads

Advanced systems offer customizable therapy addressing progression of Parkinson's disease

VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes In Patients With Deep Venous Blockages

VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes In Patients With Deep Venous Blockages

Results from the VIRTUS Study Show Venous Stent Met Its Primary Effectiveness and Safety Endpoints in Re-establishing Blood Flow at Twelve Months

Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement

Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement

Shares jump nearly 8% following agreement to pay rival Boston Scientific Corp. 4180 million to settle long-standing patent disputes.

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

All Patent Litigation Between the Companies to be Dismissed

Boston Scientific Exercises Option To Acquire Millipede, Inc.

Boston Scientific Exercises Option To Acquire Millipede, Inc.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

Boston Scientific Prevails In U.S. Edwards Lifesciences Litigation

Boston Scientific Prevails In U.S. Edwards Lifesciences Litigation

Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Healthcare has been the best performing sector of the market this year. Here are three buy-rated stocks to track now.

When Will the Pain End?: Cramer's 'Mad Money' Recap (Tuesday 11/27/18)

When Will the Pain End?: Cramer's 'Mad Money' Recap (Tuesday 11/27/18)

Jim Cramer says most - but not all - stocks are in a bear market. He talks about what's happening with Clorox, Coca-Cola, Verizon, Apple and more.

Analog Devices, MongoDB, Welltower: 'Mad Money' Lightning Round

Analog Devices, MongoDB, Welltower: 'Mad Money' Lightning Round

Jim Cramer takes a look at Analog Devices, MongoDB, Welltower, Ventas, Iridium Communications, Huntington Bancshares, Citigroup, Randgold Resources and more.

Boston Scientific to Buy Britain's BTG for $4.2 Billion

Boston Scientific to Buy Britain's BTG for $4.2 Billion

Boston Scientific offered $10.77 for each BTG share, valuing the company at $4.2 billion.

FAANGs, Retail, Housing, Boston Scientific & Renault - Five Things You Must Know

FAANGs, Retail, Housing, Boston Scientific & Renault - Five Things You Must Know

FAANG stocks are sliding into bear market territory, retail earnings dominate today's corporate calendar, housing starts and building permits will test US rate hike bets, Boston Scientific makes $4.2 billion U.K. play and Carlos Ghosn could be left by the roadside - Five Things You Must Know Before the Bell.

Boston Scientific Announces Recommended Offer To Acquire BTG Plc.

Boston Scientific Announces Recommended Offer To Acquire BTG Plc.

Transaction would expand peripheral interventions portfolio with minimally-invasive treatments for cancers and vascular conditions

Boston Scientific To Participate In Stifel 2018 Healthcare Conference

Boston Scientific To Participate In Stifel 2018 Healthcare Conference

MARLBOROUGH, Mass., Nov.

TheStreet Quant Rating: B (Buy)